

## **Abzyme to Present at MarketsandMarkets Next Gen Immuno-Oncology Congress**

**Royersford, PA, September 16, 2019.** Abzyme Therapeutics LLC will present at the 2nd Annual MarketsandMarkets Next Gen Immuno-Oncology Congress on Thursday, September 19, 2019, in Philadelphia, USA. Dr. Rajesh Singh, Laboratory Director will present at the conference at 9:40 a.m. Eastern standard time.

Dr. Singh's presentation will focus on the uniqueness and advantages of camelid VHH single domain antibodies over conventional antibodies, Abzyme's high-throughput VHH antibody development approach and application of VHHs in multi-specific antibody engineering and immunotherapy.

### **About Abzyme Therapeutics:**

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy using proprietary antibody generation platforms. Unique to Abzyme is its proprietary and highly engineered eukaryotic in vitro antibody discovery/optimization platform based on yeast display self-diversifying libraries, rapid target-directed antibody affinity maturation in combination with a FACS single cell sorting approach to identify desired antibodies. . Abzyme's modular antibody discovery platform incorporates a real-time screening ability to select for key properties such as epitopic diversity, binding affinity, expressibility, solubility, developability, broad-reactivity and target-specificity.

Today, the Company has over 60 proprietary and partnered programs in development in therapeutic and diagnostic areas including infectious diseases, immuno-oncology, ophthalmology, inflammation and central nervous system disorders.

For further information, please contact:

Abzyme Therapeutics LLC  
Steve Manobianco  
Director of Business Development  
Phone: 610-990-7531  
E-mail: [manobianco@abzymetx.com](mailto:manobianco@abzymetx.com)